RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Trovagene, Inc. today announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.

16 Jun 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Healthcare Corporate Access Day to be held on June 24, 2014

ROTH Capital Partners, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Healthcare Corporate Access Day on Tuesday, June 24, 2014, at the Dorchester Hotel in London, U.K.

11 Jun 2014

Research to identify new potential targets for cancer therapy

In 2012, about 8.2 million people died of cancer making the disease a major cause of death worldwide. According to the WHO World Cancer Report 2014, this figure is expected to rise within the next two decades.

11 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Research on viral RNA may help scientists develop treatments against infectious diseases

In an article published in the scientific journal Nature, a University of Colorado School of Medicine researcher and colleagues explain how RNA molecules found in certain viruses mimic the shape of other molecules as part of a strategy to 'hijack' the cell and make more viruses.

10 Jun 2014

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study for ISIS-DMPKRx. Isis earned a $14 million milestone payment from Biogen Idec associated with this achievement.

9 Jun 2014

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Improved diagnosis and management of one of the most common cancers in men - prostate cancer - could result from research at the research at the University of Adelaide, which has discovered that seminal fluid (semen) contains biomarkers for the disease.

9 Jun 2014

Research finding paves way for targeted approaches to treating cancer patients

Twelve years ago, UNC School of Medicine researcher Brian Strahl, PhD, found that a protein called Set2 plays a role in how yeast genes are expressed - specifically how DNA gets transcribed into messenger RNA. Now his lab has found that Set2 is also a major player in DNA repair, a complicated and crucial process that can lead to the development of cancer cells if the repair goes wrong.

9 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Scientists design nanoparticle to target tumor cells

Scientists at UC Santa Barbara have designed a nanoparticle that has a couple of unique - and important - properties.

9 Jun 2014

TSRI develops accurate structural map of complex molecular machines in cells

A team led by researchers at The Scripps Research Institute (TSRI) has used advanced electron microscopy techniques to determine the first accurate structural map of Mediator, one of the largest and most complex "molecular machines" in cells.

6 Jun 2014

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs).

6 Jun 2014

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

Caris Life Sciences and investigators from Inova Fairfax Hospital presented the first clinical outcomes data presentation from the Caris Registry™ at the 50th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., this weekend.

5 Jun 2014

INTEGRA's VIAFLO 96 handheld multichannel pipette improves efficiency of genetic screening

The Institute of Genetics and Development of Rennes, France reports on how, using a VIAFLO 96 handheld multichannel pipette from INTEGRA, they have been able to improve the efficiency and speed with which they replicate yeast strain collections and perform genetic screens in 96 well plates.

From INTEGRA Biosciences 5 Jun 2014

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncol-gicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma.

5 Jun 2014

Norgen launches 6 novel kits for simple isolation of NA from blood, plasma, serum, urine

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of 6 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA and sequential cfcDNA and cfcRNA.

5 Jun 2014

Researchers reproduce tumor chromosomal translocations in human cells

Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukaemia and Ewing's sarcoma.

4 Jun 2014

Study suggests new targets for treating rare genetic disorder and cancer

The combined action of two enzymes, Srs2 and Exo1, prevents and repairs common genetic mutations in growing yeast cells, according to a new study led by scientists at NYU Langone Medical Center.

2 Jun 2014

RNA News and Research

Further Reading

Trovagene enters into clinical collaboration with Dana-Farber Cancer Institute

Arrowhead Research joins with broad-market Russell 3000 Index

Healthcare Corporate Access Day to be held on June 24, 2014

Research to identify new potential targets for cancer therapy

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Celsion signs definitive asset purchase agreement to acquire EGEN

Research on viral RNA may help scientists develop treatments against infectious diseases

Isis Pharmaceuticals begins ISIS-DMPK Rx Phase 1 study for treatment of Myotonic Dystrophy Type 1

Certain molecules in seminal fluid indicate presence and severity of prostate cancer

Research finding paves way for targeted approaches to treating cancer patients

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Scientists design nanoparticle to target tumor cells

TSRI develops accurate structural map of complex molecular machines in cells

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Data from Caris Registry clinical outcomes presented at ASCO annual meeting

INTEGRA's VIAFLO 96 handheld multichannel pipette improves efficiency of genetic screening

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Norgen launches 6 novel kits for simple isolation of NA from blood, plasma, serum, urine

Researchers reproduce tumor chromosomal translocations in human cells

Study suggests new targets for treating rare genetic disorder and cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News